The 28 September 2022 the State-Regions Conference postponed its opinion (item 7) for the AIFA Business Plan 2022.
The plan identifies 3 corporate missions:
- guarantee the unity of the activities in the field of pharmaceuticals;
- monitor consumption and expenditure pharmaceuticals;
- favour in Italy information independent and reinvestments at R&D.
Linked to each mission are one or more guidelines (8 in total), each of which defines specific objectives measurable through ad hoc indicators and with targets to be achieved.
The AIFA 2022 activity plan was supplemented with the actions for governance pharmaceuticals whose objective is to assess the context and the actions that AIFA puts in place to ensure the sustainability of pharmaceutical expenditure.
Among them are:
- Renegotiations and contracts
- AIFA Notes - for optimal uses of drugs (prescriptive appropriateness)
- Strengthening of transparency lists
- Law 648/96 and expenditure impact (+Annex 1. Procedure for 'inclusion of drugs in the ista of L. 648/1936 after the entry into force of the Ministerial Decree of 2 August 2019 and the AIFA price negotiation guideline.
- Simplification and parallel imports
They are measures that AIFA uses to manage/reduce pharmaceutical expenditure linked to the revision of the NFP and the realignment of prices in the contracted sector.
For further details please read the summary in which we have indicated in green the actions already in place and in red those planned.
